Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

TCLs

  • Home
  •  
  • TCLs



  • Most Read
  • Latest Comments
  • FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Arovella completes development for cell therapy platform, moves to large scale manufacturing
    Arovella completes development for cell therapy platform, moves to large scale manufacturing
    • News

  • Mesoblast receives FDA support for accelerated approval pathway for heart failure treatment
    Mesoblast receives FDA support for accelerated approval pathway for heart failure treatment
    • News

  • As cash dwindles, Advanced Health Intelligence lists collabs and partnerships to turn things around
    As cash dwindles, Advanced Health Intelligence lists collabs and partnerships to turn things around
    • News

  • Noxopharm’s pancreatic cancer treatment drug slows tumour growth in mice, study shows
    Noxopharm’s pancreatic cancer treatment drug slows tumour growth in mice, study shows
    • News

  • FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    • News

  • FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    • News

    FDA grants broad orphan drug status to PTX, shoots share price up almost 30%

    Clinical state oncology company Prescient Therapeutics (ASX: PTX) has received the US FDA’s Orphan Drug Designation for its PTX-100 drug, used for cancer treatment. Previously, the Company received ODD for peripheral T-cell lymphomas (PTCL) in 2022. Following that, it applied for ODD for cutaneous T-cell lymphomas (CTCL), and it was granted a blanket designation for

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.